Welcome to the Starpharma investor centre.

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Need to update your
shareholder details

 

Download 
Annual Report

View the 
Analyst coverage

 

Have an
Investor query?

 

Register here
for email updates

Latest News & Announcements

Click here for news archive

31 January 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read more

19 January 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder Update January 2017  (pdf file, 752kb)


12 January 2017

VivaGel® BV granted QIDP and Fast Track designation by US FDA

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA).

Read more

22 December 2016

Starpharma receives $3.5M R&D tax incentive refund

Starpharma Holdings Ltd today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures. 

Read more

29 November 2016

AGM Chairman’s address and CEO presentation

Chairman’s address and the CEO’s presentation to the 2016 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Read more

28 November 2016

Starpharma signs license for VivaGel® Condom in Iran

Starpharma Holdings Ltd today announced the signing of a License and Supply Agreement with Koushan Pharmed for the sales and marketing rights to the VivaGel® condom in Iran.

Read more

26 October 2016

Starpharma to present at US Drug Delivery Conference

Starpharma will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

Read more

25 October 2016

Starpharma to present at ASX Spotlight in Asia

Starpharma presents to more than 300 sophisticated and institutional investors as part of the ASX Spotlight Conference in Hong Kong and Singapore.

Read more

13 October 2016

Enrolment complete for Phase 3 VivaGel® BV-R program

Starpharma Holdings Ltd today announced completion of patient enrolment for its pivotal phase 3 trials evaluating the efficacy and safety of VivaGel® BV for prevention of recurrent bacterial vaginosis (BV). 

 

·         100% enrolment for phase 3 trials of VivaGel® BV for prevention of recurrence

·         Trial completion expected Q1 CY2017

·         Favourable revision to FDA guidance for BV treatment product opportunity

Melbourne, Australia; 13 October 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of patient enrolment for its pivotal phase 3 trials evaluating the efficacy and safety of VivaGel® BV for prevention of recurrent bacterial vaginosis (BV). Trial completion is expected in the first quarter of calendar 2017, with topline results available early-to-mid second quarter of calendar 2017.

 

The two phase 3 trials are being conducted according to the requirements of the US Food and Drug Administration (FDA) and the European authorities to support global marketing applications for VivaGel® BV for the prevention of recurrent BV. Starpharma also secured the binding agreement of FDA on the trial design including the primary endpoint, by way of a Special Protocol Assessment (SPA). The SPA minimises regulatory risk associated with acceptance of the trial data to support marketing approval. The studies are being conducted across multiple sites in the US, Canada, Mexico, Europe and Asia.

 

The two double-blind, randomised, placebo-controlled trials are identical in design. The primary endpoint of the studies is recurrence of BV during the 16-week treatment period. The primary objective of the study is to demonstrate that the rate of BV recurrence in women using VivaGel® BV is lower than the rate of BV recurrence in women using a placebo gel during the 16-week treatment period. After the treatment period, there is a 12-week follow-up period off treatment which will assess secondary endpoints including safety.

 

Starpharma Chief Executive Officer, Dr Jackie Fairley, said: “We are delighted to have achieved full enrolment of our pivotal phase 3 trials for this indication and look forward to trial completion early next year.

 

“There are no approved products for this indication, so we have an opportunity to be first in class with VivaGel® BV for the prevention of BV recurrence. This important differentiating factor is a significant commercial advantage recognised by potential partners. There is significant unmet medical need for this chronic condition, where the global market is estimated to be worth around $1 billion annually.

 

Starpharma has already developed VivaGel® BV for bacterial vaginosis treatment separate to the prevention of recurrence indication. VivaGel® BV is approved in Europe for the treatment of BV, including relief of symptoms, and is well advanced in regulatory review in other markets, with launch planned in coming months.

 

Significantly, in a related development, the FDA recently issued a new draft clinical guidance for the development of products for BV treatment. This new guidance recommends the assessment of the primary endpoint for efficacy in treatment studies be soon after cessation of treatment (End of Treatment: day 7-14 post randomisation), and not 2‑3 weeks after treatment is ceased, which was the required timing previously. This development is particularly important as the new FDA revised End of Treatment time point is consistent with Starpharma’s 2012 phase 3 results for VivaGel® BV for treatment of BV, which showed, in both studies, highly statistically significant Clinical Cure of BV at the End of Treatment time point.

 

Starpharma has licensed VivaGel® BV to Aspen Pharmacare for Australia and New Zealand and has advanced negotiations underway with a number of parties for other regions, including Europe. Naturally, the shift in FDA requirements has positive implications in terms of partnering for VivaGel® BV - for both the treatment and the prevention of recurrent BV product opportunities.

 

The FDA draft guidance is available:  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510948.pdf.

 

About VivaGel® BV

VivaGel® (SPL7013, astodrimer sodium) is a non-antibiotic agent formulated as a vaginally applied gel (VivaGel® BV) for treatment of BV and prevention of BV recurrence. VivaGel® BV has been approved in Europe as a topical treatment for the rapid relief of BV, including symptoms of unpleasant vaginal odour and discharge.

 

About Bacterial Vaginosis (BV)

Bacterial vaginosis is the most common cause of vaginal infection for women of childbearing age, and affects around 30% of women in the US. It is a highly recurrent condition with 50-60% of sufferers having it recurrently. BV is caused by an imbalance of naturally occurring bacterial flora (the usual bacteria found in a woman's vagina). Smoking, the use of some hygiene products and several other risk factors are linked to a higher risk of developing BV. The global market value for the prevention of recurrent BV is estimated to be more than US$1 billion.

 

Read more

13 September 2016

VivaGel® condom receives regulatory approval in Canada

Starpharma today announced it had been granted a medical device license for the VivaGel® condom by the Canadian regulatory authority, Health Canada.

Read more

30 August 2016

Highlights of FY2016 Presentation: FNN Interview

Starpharma advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.

Read more

29 August 2016

Annual Report and full year financial results

Starpharma released its annual report and financial results for the year ended 30 June 2016.

 Financial Results

  • Net cash burn (cash outflows before new capital) $17.5M
  • Cash position at end of the year $46.0M
  • Net proceeds of $32.6M from equity placement and share purchase plan
  • Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
  • Reported loss $22.7M
  • Receipt of $3.4M R&D tax incentive
Read more
12 ... Next

Reports & Presentations

Click here for financial reports archive

31 January 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read more

8 November 2016

Starpharma to present at Bio-Europe conference

Starpharma will be presenting at the Bio-Europe® conference held in Cologne, Germany this week. At the conference Starpharma will also be conducting licensing discussions for DEP™ and VivaGel® with pharmaceutical companies.

Read more

26 October 2016

Starpharma to present at US Drug Delivery Conference

Starpharma will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

Read more

25 October 2016

Starpharma to present at ASX Spotlight in Asia

Starpharma presents to more than 300 sophisticated and institutional investors as part of the ASX Spotlight Conference in Hong Kong and Singapore.

Read more

30 August 2016

Highlights of FY2016 Presentation: FNN Interview

Starpharma advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.

Read more

29 August 2016

Annual Report and full year financial results

Starpharma released its annual report and financial results for the year ended 30 June 2016.

 Financial Results

  • Net cash burn (cash outflows before new capital) $17.5M
  • Cash position at end of the year $46.0M
  • Net proceeds of $32.6M from equity placement and share purchase plan
  • Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
  • Reported loss $22.7M
  • Receipt of $3.4M R&D tax incentive
Read more

In the Media

Click here for more In the Media

1 August 2016

The Australian: Starpharma perks up on China condom deal

The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.

Go to the article (external link)

17 May 2016

The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

© Starpharma Holdings Limited 2017